User profiles for T.J. Witek
 | Theodore J Witek, JrProfessor and Senior Fellow, IHPME, University of Toronto Verified email at utoronto.ca Cited by 4894 |
Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease
B Disse, GA Speck, KL Rominger, TJ Witek Jr… - Life sciences, 1999 - Elsevier
Inhaled antimuscarinics, often called anticholinergics in clinical medicine, are established
as first line bronchodilators in COPD. Tiotropium has been developed as a new generation …
as first line bronchodilators in COPD. Tiotropium has been developed as a new generation …
The MCID of the transition dyspnea index is a total score of one unit
DA Mahler, TJ Witek Jr - COPD: Journal of Chronic Obstructive …, 2005 - Taylor & Francis
The Baseline (BDI) and Transition (TDI) Dyspnea Indexes provide interview-based
measurements of breathlessness related to activities of daily living. The BDI is a discriminative …
measurements of breathlessness related to activities of daily living. The BDI is a discriminative …
A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
…, ED Bateman, SJ Langley, A Lee, TJ Witek Jr… - Chest, 2002 - Elsevier
Background Tiotropium, a once-daily anticholinergic, and salmeterol represent two inhaled,
long-acting bronchodilators from different pharmacologic classes. A trial was designed to …
long-acting bronchodilators from different pharmacologic classes. A trial was designed to …
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD
R Casaburi, D Kukafka, CB Cooper, TJ Witek Jr… - Chest, 2005 - Elsevier
… TJ Witek Jr, DA Mahler … Witek and Kesten areemployees of Boehringer-Ingelheim
Pharmaceuticals. This study was supported by Boehringer-Ingelheim Pharmaceuticals Inc. and …
Pharmaceuticals. This study was supported by Boehringer-Ingelheim Pharmaceuticals Inc. and …
Frequency and natural history of rhinovirus infections in adults during autumn
E Arruda, A Pitkäranta, TJ Witek Jr… - Journal of clinical …, 1997 - Am Soc Microbiol
Human rhinovirus (HRV) accounts for a significant portion of common-cold illness, with the
peak incidence being in the early fall. Three hundred forty-six adults who had self-diagnosed …
peak incidence being in the early fall. Three hundred forty-six adults who had self-diagnosed …
[HTML][HTML] The emergency use authorization of pharmaceuticals: history and utility during the COVID-19 pandemic
A Tran, TJ Witek Jr - Pharmaceutical Medicine, 2021 - Springer
The Emergency Use Authorization (EUA) originated in 2004 because of the need for emergency
medical countermeasures (MCMs) against potential bioterrorist attacks. The EUA also …
medical countermeasures (MCMs) against potential bioterrorist attacks. The EUA also …
Formaldehyde (CH2O) Concentrations in the Blood of Humans and Fischer-344 Rats Exposed to CH2O Under Controlled Conditions
…, PB DODD, EN SCHACHTER, TJ WITEK… - American Industrial …, 1985 - Taylor & Francis
The effect of exposure to formaldehyde (CH 2 O) on the CH 2 O concentration of the blood
was determined. Eight male F-344 rats were exposed to 14.4 ± 2.4 ppm of CH 2 O for 2 hours …
was determined. Eight male F-344 rats were exposed to 14.4 ± 2.4 ppm of CH 2 O for 2 hours …
Minimal important difference of the transition dyspnoea index in a multinational clinical trial
TJ Witek, DA Mahler - European Respiratory Journal, 2003 - Eur Respiratory Soc
Dyspnoea is a primary symptom of chronic obstructive pulmonary disease (COPD). The
baseline (BDI) and transition (TDI) dyspnoea indices are commonly used instruments to assess …
baseline (BDI) and transition (TDI) dyspnoea indices are commonly used instruments to assess …
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
…, CW Serby, SS Menjoge, TJ Witek Jr - American journal of …, 2000 - atsjournals.org
Tiotropium (Spiriva; Ba679BR) is a new-generation, long-acting anticholinergic bronchodilator
that has muscarinic M 1 and M 3 receptor subtype selectivity. A multicenter, randomized, …
that has muscarinic M 1 and M 3 receptor subtype selectivity. A multicenter, randomized, …
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial
…, JF Donohue, CW Serby, SS Menjoge, TJ Witek Jr… - Chest, 2000 - Elsevier
Study objective To compare the bronchodilator efficacyand safety of tiotropium and placebo.
Design A3-month, randomized, double-blind, placebo-controlled, multicentertrial. Setting …
Design A3-month, randomized, double-blind, placebo-controlled, multicentertrial. Setting …